Compare Google Inc (GOOG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Recursion Pharmaceuticals Inc — how do they compare? Google Inc trades at $372.39 (market cap $4.52T), while Recursion Pharmaceuticals Inc trades at $3.17 (market cap $1.75B). The key difference: Google Inc is far larger — about 2582.9× Recursion Pharmaceuticals Inc's market cap, and Google Inc pays a 0.24% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GOOG | RXRX | |
|---|---|---|
Market Cap | $4.52T | $1.75B |
Volume | 1,511,127 | — |
Sector | Technology | Health |
52-Week High | $399.06 | $6.79 |
52-Week Low | $183.77 | $2.84 |
Enterprise Value | $4.49T | $1.17B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GOOG trades at $357.33, up 1.9% today, with a bullish technical signal and strong support at $353. The company shows robust fundamentals with 2025 revenue of $402.84B, net income of $132.17B, and a net margin of 32.8%. Recent earnings beats and a consensus analyst price target of $457.50 highlight positive momentum, while news includes Warren Buffett's endorsement and strategic AI partnerships.
Outlook remains positive driven by earnings growth and AI expansion, but risks include regulatory fines and competitive pressures. Wall Street sentiment is strongly bullish with 87% buy ratings, suggesting upside potential, though investors should monitor execution and macroeconomic factors.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
